Flor M Munoz1. 1. Department of Pediatrics and Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Respiratory syncytial virus (RSV) remains an important cause of serious and sometimes fatal acute lower respiratory tract disease in infants, yet no effective antiviral treatment or vaccine for the prevention of RSV in early life is available. Vaccination of women during pregnancy is considered to be the most plausible strategy to provide direct RSV antibody protection to young infants during a period of greatest vulnerability. RECENT FINDINGS: Interest in the development of RSV vaccines for immunization of women during pregnancy is high. Numerous studies are underway to better understand the epidemiology and impact of RSV disease in pregnant women and infants, as well as the role of maternal antibodies in the protection of infants against early and severe RSV disease, to identify and measure serologic correlates of protection to RSV in infants and develop well tolerated and immunogenic RSV vaccines for pregnant women. SUMMARY: Studies of RSV vaccination in pregnancy are in progress, making maternal vaccination a realistic intervention for the protection of young infants against RSV disease in the near future. Maternal immunization with an immunogenic vaccine has the potential to substantially impact the morbidity and mortality of RSV-associated lower respiratory tract illness in infants worldwide.
PURPOSE OF REVIEW: Respiratory syncytial virus (RSV) remains an important cause of serious and sometimes fatal acute lower respiratory tract disease in infants, yet no effective antiviral treatment or vaccine for the prevention of RSV in early life is available. Vaccination of women during pregnancy is considered to be the most plausible strategy to provide direct RSV antibody protection to young infants during a period of greatest vulnerability. RECENT FINDINGS: Interest in the development of RSV vaccines for immunization of women during pregnancy is high. Numerous studies are underway to better understand the epidemiology and impact of RSV disease in pregnant women and infants, as well as the role of maternal antibodies in the protection of infants against early and severe RSV disease, to identify and measure serologic correlates of protection to RSV in infants and develop well tolerated and immunogenic RSV vaccines for pregnant women. SUMMARY: Studies of RSV vaccination in pregnancy are in progress, making maternal vaccination a realistic intervention for the protection of young infants against RSV disease in the near future. Maternal immunization with an immunogenic vaccine has the potential to substantially impact the morbidity and mortality of RSV-associated lower respiratory tract illness in infants worldwide.
Authors: Srirupa Chatterjee; Priya Luthra; Ekaterina Esaulova; Eugene Agapov; Benjamin C Yen; Dominika M Borek; Megan R Edwards; Anuradha Mittal; David S Jordan; Parameshwar Ramanan; Martin L Moore; Rohit V Pappu; Michael J Holtzman; Maxim N Artyomov; Christopher F Basler; Gaya K Amarasinghe; Daisy W Leung Journal: Nat Microbiol Date: 2017-06-30 Impact factor: 17.745
Authors: Claire M Midgley; Amber K Haynes; Jason L Baumgardner; Christina Chommanard; Sara W Demas; Mila M Prill; Glen R Abedi; Aaron T Curns; John T Watson; Susan I Gerber Journal: J Infect Dis Date: 2017-08-01 Impact factor: 5.226
Authors: Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel Journal: Hum Vaccin Immunother Date: 2018-06-19 Impact factor: 3.452
Authors: Christine E Jones; Flor M Munoz; Hans M L Spiegel; Ulrich Heininger; Patrick L F Zuber; Kathryn M Edwards; Philipp Lambach; Pieter Neels; Katrin S Kohl; Jane Gidudu; Steven Hirschfeld; James M Oleske; Najwa Khuri-Bulos; Jorgen Bauwens; Linda O Eckert; Sonali Kochhar; Jan Bonhoeffer; Paul T Heath Journal: Vaccine Date: 2016-07-29 Impact factor: 3.641